Literature DB >> 1362727

The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells.

A Chadburn1, G Inghirami, D M Knowles.   

Abstract

Cell surface antigens, including CD71 (T9), CD38 (T10), HLA-DR, CD25 (IL2-R), CD15 (LeuM1), CD30 (Ki-1), epithelial membrane antigen (EMA), and CD11c (LeuM5), have been identified on the surface of neoplastic T-cells. The significance of this expression is unknown since the expression of these antigens by benign T cells has not been fully investigated. In this study the kinetics, temporal relation and hierarchy of expression of these eight cell surface antigens by purified normal peripheral blood T cells following activation with phytohemagglutinin (PHA) were investigated using one- and two-color flow cytometry. All eight antigens were expressed in a hierarchical manner following activation of normal peripheral blood T cells with PHA. The sequence of antigen expression and the initial time point of this expression was: CD38, < 24 h; CD71, CD25, 24 h; EMA, HLA-DR, CD15, 48-72 h; CD30, 72 h; and CD11c, 96-120 h. The maximum percentage of T cells expressing each antigen and the time point of maximum expression was: CD38 96% at 14 and 17 days; CD71 88%, CD25 94%, EMA 55%, and CD30 31% at 96 h; CD15 56% at 120 h; HLA-DR 30% at 168 h; and CD11c 42% at 240 h. The expression of these 8 antigens clustered into six distinct immunophenotypic constellations: Group I: None; Group II: CD38 with CD71 and/or CD25; Group III: CD38, CD71, CD25 with HLA-DR, CD15 and/or EMA; Group IV: CD38, CD71, CD25, EMA, HLA-DR with CD15, CD30 and/or CD11c; Group V: CD38, CD25, CD11c with CD71, EMA and/or HLA-DR; Group VI: CD38 with CD25 and/or CD11c. Finally, EMA and CD11c were preferentially expressed by CD4 and CD8 T cells, respectively. In summary, these results demonstrate that all eight antigens (1) are associated with T-cell activation, (2) are expressed in a hierarchical manner following activation, and (3) that this expression clusters into distinct immunophenotypic constellations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362727

Source DB:  PubMed          Journal:  Hematol Pathol        ISSN: 0886-0238


  10 in total

1.  Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis.

Authors:  Mehdi Najar; Gordana Raicevic; Hussein Fayyad-Kazan; Cécile De Bruyn; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

Review 2.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

3.  Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach.

Authors:  A Johannisson; A Thuvander; I L Gadhasson
Journal:  Cell Biol Toxicol       Date:  1995-12       Impact factor: 6.691

4.  EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Authors:  Janine Schmidt; Irina Bonzheim; Julia Steinhilber; Ivonne A Montes-Mojarro; Carlos Ortiz-Hidalgo; Wolfram Klapper; Falko Fend; Leticia Quintanilla-Martínez
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

5.  Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre.

Authors:  A Horst; N Hunzelmann; S Arce; M Herber; R A Manz; A Radbruch; R Nischt; J Schmitz; M Assenmacher
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

6.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

7.  CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer.

Authors:  Michelle Hong; Jian Hang Lam; Si-Lin Koo; Clarinda Wei Ling Chua; Kah Ling Lim; Felicia Wee; Wei Keat Wan; Wei Qiang Leow; Joo Guan Yeo; Iain Bee Huat Tan; Joe Yeong; Tony Kiat Hon Lim; Tong Seng Lim
Journal:  Cancer Immunol Immunother       Date:  2021-02-02       Impact factor: 6.630

Review 8.  Acute myeloid leukemia targets for bispecific antibodies.

Authors:  S S Hoseini; N K Cheung
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

9.  One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.

Authors:  Christina Psomas; Mehwish Younas; Christelle Reynes; Renaud Cezar; Pierre Portalès; Edouard Tuaillon; Adeline Guigues; Corinne Merle; Nadine Atoui; Céline Fernandez; Vincent Le Moing; Claudine Barbuat; Grégory Marin; Nicolas Nagot; Albert Sotto; Jean-François Eliaou; Robert Sabatier; Jacques Reynes; Pierre Corbeau
Journal:  EBioMedicine       Date:  2016-05-10       Impact factor: 8.143

10.  Complement-Opsonized HIV-1 Alters Cross Talk Between Dendritic Cells and Natural Killer (NK) Cells to Inhibit NK Killing and to Upregulate PD-1, CXCR3, and CCR4 on T Cells.

Authors:  Rada Ellegård; Mohammad Khalid; Cecilia Svanberg; Hanna Holgersson; Ylva Thorén; Mirja Karolina Wittgren; Jorma Hinkula; Sofia Nyström; Esaki M Shankar; Marie Larsson
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.